The 3 most recent market catalysts affecting $VAL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 27, 2026
Corporate Catalyst
Bearish
Impact 85
Valion Bio shares are trading lower after the company announced a 1-for-25 reverse stock split.
A reverse stock split, especially one as aggressive as 1-for-25, is generally perceived negatively by the market. It often indicates that the company's stock price has fallen to da…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 85
Valaris Q2 EPS $0.72 Beats $0.23 Estimate, Sales $539.200M Beat $494.490M Estimate
Valaris announced Q2 earnings of $0.72 per share, significantly surpassing the $0.23 analyst consensus, and sales of $539.2 million, also beating the $494.49 million estimate. This…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 65
Valion Bio shares are trading lower. The company announced a clinical development milestone with the finalization of a clinical trial protocol at Sheba Medical Center.
The headline presents a mixed signal: a positive operational milestone (finalizing a clinical trial protocol) is met with a negative market reaction (shares trading lower). This su…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.